Diannexin reduces no-reflow after reperfusion in rabbits with large ischemic myocardial risk zones

Cardiovascular Therapeutics

Volumn 29, Issue 4, 2011, Pages e42-e52

  Hale, Sharon L ^a   Allison, Anthony C ^b   Kloner, Robert A ^a,c  

^a GOOD SAMARITAN HOSPITAL   (United States)

^b Alavita Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Diannexin; Infarct size; Myocardial infarction; No reflow; Rabbit

Indexed keywords

DIANNEXIN; LIPOCORTIN 5; PHOSPHATIDYLSERINE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; BLOOD FLOW; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY REPERFUSION; ENZYME BINDING; HEART HEMODYNAMICS; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART PROTECTION; MALE; NO REFLOW; NONHUMAN; PRIORITY JOURNAL; RABBIT; RISK ASSESSMENT; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

EID: 79960271906     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2010.00223.x     Document Type: Article

References (35)

1. Ito H. No-reflow phenomenon in patients with acute myocardial infarction: Its pathophysiology and clinical implications. Acta Med Okayama 2009;63:161-168. Review.
2. Niccoli G, D'amario D, Spaziani C, et al. Randomized evaluation of intracoronary nitroprusside vs. adenosine after thrombus aspiration during primary percutaneous coronary intervention for the prevention of no-reflow in acute myocardial infarction: The REOPEN-AMI study protocol. J Cardiovasc Med (Hagerstown) 2009;10:585-592.
3. Lee HC, An SG, Choi JH, et al. Effect of intra-coronary nicorandil administration prior to reperfusion in acute ST segment elevation myocardial infarction. Circ J 2008;72:1425-1429.
4. Matsuo H, Watanabe S, Watanabe T, et al. Prevention of no-reflow/slow-flow phenomenon during rotational atherectomy: A prospective randomized study comparing intracoronary continuous infusion of verapamil and nicorandil. Am Heart J 2007;154:994.e1-6. Epub 2007 Sep 14.
5. Parikh KH, Chag MC, Shah KJ, et al. Intracoronary boluses of adenosine and sodium nitroprusside in combination reverses slow/no-reflow during angioplasty: A clinical scenario of ischemic preconditioning. Can J Physiol Pharmacol 2007;85:476-482.
6. Amit G, Cafri C, Yaroslavtsev S, et al. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial. Am Heart J 2006;152:887.e9-887.e14.
7. Ota S, Nishikawa H, Takeuchi M, et al. Impact of nicorandil to prevent reperfusion injury in patients with acute myocardial infarction: Sigmart Multicenter Angioplasty Revascularization Trial (SMART). Circ J 2006;70:1099-1104.
8. Umemura S, Nakamura S, Sugiura T, et al. The effect of verapamil on the restoration of myocardial perfusion and functional recovery in patients with angiographic no-reflow after primary percutaneous coronary intervention. Nucl Med Commun 2006;27:247-254.
9. Micari A, Belcik TA, Balcells EA, Powers E, Wei K, Kaul S, Lindner JR. Improvement in microvascular reflow and reduction of infarct size with adenosine in patients undergoing primary coronary stenting. Am J Cardiol 2005;96:1410-1415.
10. Hang CL, Wang CP, Yip HK, Yang CH, Guo GB, Wu CJ, Chen SM. Early administration of intracoronary verapamil improves myocardial perfusion during percutaneous coronary interventions for acute myocardial infarction. Chest 2005;128:2593-2598.
11. Kuypers PF, Larkin SK, Emeis JJ, Allison AC. Interaction of an annexin V homodimer (Diannexin) with phosphatidylserine on cell surfaces and consequent antithrombotic activity. Thromb Haemost 2007;97:478-486.
12. Teoh NC, Field J, Bethea NW, et al. Diannexin, a novel annexin V homodimer, provides prolonged protection against hepatic ischemia-reperfusion injury in mice. Gastroenterology 2007;133:632-646.
13. Shen XD, Ke B, Zhai Y, et al. Diannexin, a novel annexin V homodimer, protects rat liver transplants against cold ischemia-reperfusion injury. Am J Transplant 2007;7:2463-2471.
14. Molski M, Groth A, Allison AC, Hendrickson M, Siemionow M. Diannexin treatment decreases ischemia-reperfusion injury at the endothelial cell level of the microvascular bed in muscle flaps. Ann Plastic Surgery 2009;63:564-571.
15. Cooper M, Kapur S, Stratta R, Mulgaonkar A, Allison A, Russell M, Knectle S. A phase 2, two-part study of the safety and tolerability of Diannexin in kidney transplant recipients. Protocol DAV-CLOO2, 12-JAN-2010. In: Data on file, Mountain View, CA Alavita Pharmaceuticals.
16. Rasband WS. Image J. Bethesda, Md, USA National Institutes of Health, [Accessed 28 July 2010].
17. Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after temporary coronary occlusion in dogs. J Clin Invest 1974;54:1496-1508.
18. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation 2002;105:656-662.
19. Reffelmann T, Hale SL, Li G, Kloner RA. Relationship between no reflow and infarct size as influenced by the duration of ischemia and reperfusion. Am J Physiol Heart Circ Physiol 2001;282:H766-H772.
20. Reffelmann T, Kloner RA. The no-reflow phenomenon: A basic mechanism of myocardial ischemia and reperfusion. Basic Res Cardiol 2006;101:359-372. Review.
21. Soupene E, Kuypers FA. Identification of an erythroid ATP-dependent aminophospholipid transporter. Brit J Hematol 2006;133:436-438.
22. Ran S, Downes A, Thorpe PE. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res 2002;62:6132-6140.
23. Rongen GA, Oyen WJG, Ramakers BP, Riksen NP, Boerman OC, Steinmetz N, Smits P. Annexin A5 scintigraphy of forearm as a novel in vivo model of skeletal muscle preconditioning in humans. Circulation 2005;111:173-178.
24. Kenis H, Zandbergen H, Hofstra L, et al. Annexin A5 uptake in ischemic myocardium: Demonstration of reversible phosphatidylserine externalization and feasibility of radionuclide imaging. J Nucl Med 2010;51:259-267.
25. Pohl A, Lage H, Muller P, Pomorski T, Herrmann A. Transport of phosphatidylserine via MDR1 (multidrug resistance 1) P-glycoprotein in a human gastric carcinoma cell line. Biochem J 2002;365:259-268.
26. Huls M, Kramers C, Levtchenko EN, et al. P-glycoprotein-deficient mice have proximal tubule dysfunction but are protected against ischemic renal injury. Kidney Internat 2007;72:1233-1241.
27. Potschka H, Battes S, Löscher W. Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats. Epilepsy Res 2004;58:85-91.
28. Ravichandran KS, Lorenz U. Engulfment of apoptotic cells: Signals for a good meal. Nature Revs Immunol 2007;7:964-974.
29. Rand ML, Gross PL, Wang H, Allison AC, Plythero FG, Kahr WH. In vitro and in vivo antithrombotic effects of diannexin, a novel homodimer of annexin A5. J Thromb Haemostasis 2009;7(Suppl 2):OC-TII-060.
30. Renne T, Pozgajova M, Gruner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005;202:278-281.
31. Okajima K, Harada N, Kushimoto S, Uchiba M. Role of microthrombus formation in the development of ischemia/reperfusion-induced liver injury in rats. Thromb Haemost 2002;88:473-480.
32. Aronowski J, Strong R, Grotta JC. Reperfusion injury: Demonstration of brain damage produced by reperfusion after transient focal ischemia in rats. J Cereb Blood Flow Metab 1997;17:1048-1056.
33. Jormalainen M, Vento AE, Wartiovaara-Kautto U, Suojaranta-Ylinen R, Rämö OJ, Petäjä J. Recombinant hirudin enhances cardiac output and decreases systemic vascular resistance during reperfusion after cardiopulmonary bypass in a porcine model. J Thor Cardiovasc Surg 2004;128:189-196.
34. Manciet LH, Poole DC, McDonagh PF, Copeland JG, Mathieu-Costello O. Microvascular compression during myocardial ischemia: Mechanistic basis for no-reflow phenomenon. Am J Physiol 1994;266:H1541-H1550.
35. Maier CM, Hsieh L, Crandall T, Narasimhan P, Chan PH. Evaluating therapeutic targets for reperfusion-related brain hemorrhage. Ann Neurol 2006;59:929-938.